These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12198335)

  • 21. Is a combination of verapamil and an ACE-inhibitor the optimal solution in ischaemic heart failure?
    Jespersen CM
    Cardiologia; 1995 Dec; 40(12 Suppl 1):307-10. PubMed ID: 8903054
    [No Abstract]   [Full Text] [Related]  

  • 22. Chronotherapeutics: are there meaningful differences among antihypertensive drugs?
    Poirier L; Lefebvre J; Lacourciere Y
    Curr Hypertens Rep; 1999 Aug; 1(4):320-7. PubMed ID: 10981084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Indications for calcium channel antagonist therapy according to the latest large clinical trials].
    Kosicka T; Kara-Perz H; Głuszek J; Perz S
    Pol Arch Med Wewn; 2005 Dec; 114(6):1244-51. PubMed ID: 16789496
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical pharmacology-physiology conference. A chrono-therapeutic approach to the treatment of hypertension.
    Lowenthal DT; Estrada J; Cott R
    Int Urol Nephrol; 2001; 33(2):265-8. PubMed ID: 12092639
    [No Abstract]   [Full Text] [Related]  

  • 25. [An evaluation of the efficacy of treating IHD patients with calcium antagonists].
    Mordovin VF; Triss SV; Fedorova NA; Chernov VI; Krylov A; Pavliukova EN; Karpov RS
    Ter Arkh; 1995; 67(6):5-8. PubMed ID: 7667781
    [No Abstract]   [Full Text] [Related]  

  • 26. Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial.
    Deanfield JE; Detry JM; Sellier P; Lichtlen PR; Thaulow E; Bultas J; Brennan C; Young ST; Beckerman B;
    J Am Coll Cardiol; 2002 Sep; 40(5):917-25. PubMed ID: 12225716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcium channel blockers in systemic hypertension.
    Frishman WH; Charlap S; Michelson EL
    Am J Cardiol; 1986 Jul; 58(1):157-60. PubMed ID: 3524178
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacology of cardiovascular chronotherapeutic agents.
    Smith DH
    Am J Hypertens; 2001 Sep; 14(9 Pt 2):296S-301S. PubMed ID: 11583143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension.
    White WB
    Am J Hypertens; 1999 Feb; 12(2 Pt 2):50S-55S. PubMed ID: 10090295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.
    Leon MB; Rosing DR; Bonow RO; Epstein SE
    Am J Cardiol; 1985 Jan; 55(3):69B-80B. PubMed ID: 2857518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-series analysis of long-term ambulatory myocardial ischemia: effects of beta-adrenergic and calcium channel blockade.
    Lambert CR; Raymenants E; Pepine CJ
    Am Heart J; 1995 Apr; 129(4):677-84. PubMed ID: 7900617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine.
    Conti CR
    Am J Cardiol; 1996 Nov; 78(9A):13-8. PubMed ID: 8903280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amlodipine versus diltiazem CR in the reduction of the total ischemic burden: the Circadian Anti-Ischemia Program in Europe (CAPE) II trial--clinical rationale and methodology.
    Deanfield JE
    Cardiovasc Drugs Ther; 1998 Oct; 12 Suppl 3():239-42. PubMed ID: 9800053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases.
    Ezeugo U; Glasser SP
    Expert Opin Pharmacother; 2009 Feb; 10(3):485-91. PubMed ID: 19191683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization.
    Davies RF; Goldberg AD; Forman S; Pepine CJ; Knatterud GL; Geller N; Sopko G; Pratt C; Deanfield J; Conti CR
    Circulation; 1997 Apr; 95(8):2037-43. PubMed ID: 9133513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
    Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
    JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring.
    Watts RW; Wing LM
    Blood Press; 1998 Jan; 7(1):25-30. PubMed ID: 9551874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension.
    White WB; Elliott WJ; Johnson MF; Black HR
    J Hum Hypertens; 2001 Feb; 15(2):135-41. PubMed ID: 11317194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of the antihypertensive efficacy and safety of using sustained release verapamil in elderly subjects using ambulatory blood pressure monitoring].
    Jasiński T; Janicki K; Klima M; Pieniazek W; Bednarz S
    Przegl Lek; 1996; 53(2):73-7. PubMed ID: 8754325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of nitrendipine on circadian variation of blood pressure in inpatients with renal parenchymal hypertension: assessment by ambulatory blood pressure monitoring].
    Ideura T; Miyazaki M; Uchida K; Sakaguchi K; Kawano Y
    Nihon Jinzo Gakkai Shi; 2004 Jul; 46(5):434-41. PubMed ID: 15446599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.